Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 474121 in Healthy Men
NCT04194645Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 474121 in schizophrenia (15 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of Subjects With Drug-related Adverse Events at 7 days, Area Under the Concentration-time Curve of BI 474121 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point and 1 more. Started Jan 2020; status: completed.
02
Drugs
BI 474121
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04194645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194645.